TNFRSF17 and Miyoshi myopathy: In an extensive series of 476 MM patients, the serological response after one week from the third dose injection in patients who did not develop SARS-CoV-2 resulted in significant increases of anti-S IgG across all treatment groups, including in patients receiving an anti-CD38 or anti-BCMA-targeted therapy (18).